Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a report issued on Monday. The firm issued a hold rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

CTLT opened at $63.48 on Monday. Catalent has a 1 year low of $41.15 and a 1 year high of $63.50. The company’s 50 day simple moving average is $62.24 and its 200 day simple moving average is $60.47. The stock has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the firm earned ($0.10) EPS. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, sell-side analysts expect that Catalent will post 0.78 EPS for the current year.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Brooklyn Investment Group acquired a new stake in shares of Catalent during the third quarter worth $31,000. Sentry Investment Management LLC acquired a new stake in Catalent during the third quarter worth about $53,000. Thurston Springer Miller Herd & Titak Inc. raised its stake in Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the period. Intact Investment Management Inc. bought a new position in Catalent in the third quarter worth about $73,000. Finally, GAMMA Investing LLC boosted its stake in Catalent by 26.9% in the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after acquiring an additional 278 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.